Shares of Exelixis (NASDAQ:EXEL) reached a new 52-week low on Thursday after Credit Suisse lowered their price target on the stock from $6.00 to $5.00, AnalystRatings.NET reports. Exelixis, Inc. (NASDAQ:EXEL) shares after opening at $4.07 moved to $4.08 on last trade day and at the end of the day closed at $3.86. Company price to sales ratio in past twelve months was calculated as 22.74 and price to cash ratio as 2.79. Exelixis, Inc. (NASDAQ:EXEL) showed a negative weekly performance of -40.62%.
BioTime, Inc. (NYSE MKT:BTX) announced the results of its capital raising activities since October 1, 2013 through its $25 million Controlled Equity Offering facility, and through sales of BioTime common shares by certain of its subsidiaries, in “at-the-market” transactions through Cantor Fitzgerald & Co., as sales agent. BioTime, Inc. (NYSEMKT:BTX) shares fell -0.61% in last trading session and ended the day on $3.24. BTX return on equity ratio is recorded as -321.10% and its return on assets is -126.30%. BioTime, Inc. (NYSEMKT:BTX) yearly performance is -15.18%.
Celsion Corp. (CLSN) announced positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial will enroll 20 patients at 5 clinical sites in the United States and is evaluating ThermoDox in combination with mild hyperthermia. Celsion Corporation (NASDAQ:CLSN) shares moved up 2.06% in last trading session and was closed at $3.46, while trading in range of $3.36 – 3.52 . Celsion Corporation (NASDAQ:CLSN) year to date (YTD) performance is -11.05%.
Onconova Therapeutics (NASDAQ: ONTX) shares declined 3.79% to touch a new 52-week low of $6.85. Onconova’s trailing-twelve-month EPS is -$6.12. Onconova Therapeutics Inc (NASDAQ:ONTX) weekly performance is -10.03%. On last trading day company shares ended up $6.64. Onconova Therapeutics Inc (NASDAQ:ONTX) distance from 50-day simple moving average (SMA50) is -38.65%. Analysts mean target price for the company is $11.50.